Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Yestar Aesthetic Medical / Equity Capital Markets

<p>Yestar, a leading aesthetic medical chain in China, is seeking to list in Hong Kong. In this insight, we will cover the following topics:</p>
<ul>
<li>The business lines of the company</li>
<li>Growth drivers</li>
<li>Risk of the business</li>
<li>Company history and shareholders</li>
<li>Initial thoughts on valuation</li>
</ul>
<p>We have seen red flags that we would simply pass the deal.</p>

Yestar, a leading aesthetic medical chain in China, is seeking to list in Hong Kong. In this insight, we will cover the following topics:

The business lines of the company
Growth drivers
Risk of the business
Company history and shareholders
Initial thoughts on valuation

We have seen red flags that we would simply pass the deal.

Yestar Aesthetic Medical (艺星医疗) IPO: Founders' Origin and Red Flags Matter

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Yestar Aesthetic Medical (YES HK)

Yestar Aesthetic Medical (艺星医疗) IPO: Founders' Origin and Red Flags Matter

Yestar, a leading aesthetic medical chain in China, is seeking to list in Hong Kong. In this insight, we will cover the following...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)